· UZEDY revenue forecast for Teva in 2024: ~$80 million
· Ongoing phase 3 of Olanzapine LAI: l675 patients (recruitment completed), 62% of 3,600 planned injections completed, no PDSS (post-injection sedation syndrome) observed
About UZEDY
During Teva Pharmaceutical Industries Ltd.’s fourth quarter earnings call, Chairman and CEO Richard Francis said he expects strong adoption of UZEDY as well as significant sales growth in 2024. He said also gave revenue forecasts for UZEDY in 2024, estimated at around $80 million.
This forecast is aligned with MedinCell’s anticipated revenue from UZEDY sales, with the company receiving royalties on all sales and being eligible for $105 million in commercial milestones.